A Community Advocate on the Global Stage
An Interview with Shaun Mellors
"How many silences have you broken since Durban? How many more still need to be broken?"
Barcelona 2002, Vaccine Satellite, Superinfection?, Barcelona Sessions, IAVI Outlines R&D Plans for Next Two Years A Community Advocate on the Global Stage Therapeutic Vaccine New Vaccines in the Pipeline Vaccine Briefs
An Interview with Shaun Mellors
"How many silences have you broken since Durban? How many more still need to be broken?"
This issue of the IAVI Report is devoted to a collection of articles on key themes in vaccines at the XIVth International AIDS Conference
By Patricia Kahn, Ph.D.*
Is the AIDS vaccine glass half full or half empty? With a host of animal studies on candidates that fail to protect against infection but delay or prevent disease, it can be difficult to tell—especially since it’s not known whether results from animal studies are predictive of what will be seen in humans.
By Patricia Kahn, Ph.D.*
At the Barcelona meeting, IAVI released its Research and Development Agenda 2002-2004.
The growing number of candidates in pre-clinical development featured heavily in the vaccine presentations at Barcelona, along with updates on products already in clinical trials.
By Patricia Kahn, Ph.D.*
Barcelona introduced a new word—and a new worry—into the common AIDS parlance: superinfection.
By Patricia Kahn, Ph.D.*
On the final afternoon of the meeting, Julianna Lisziewicz of the Research Institute for Genetic and Human Therapy (Washington, DC) presented encouraging preliminary data on a therapeutic vaccine used together with structured treatment interruption in chronically infected monkeys—among the first hints of success in immune treatment of chronic infection (Abstract #ThPpA2128).
Gro Harlem Brundtland Steps Down from WHO
By Patricia Kahn, Ph.D.*
For the first time since the International AIDS Conferences began in 1983, this year’s event featured an official satellite meeting on vaccines.